Financhill
Sell
32

ALT Quote, Financials, Valuation and Earnings

Last price:
$5.90
Seasonality move :
-9.61%
Day range:
$5.36 - $6.05
52-week range:
$5.14 - $11.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20,948.16x
P/B ratio:
3.68x
Volume:
12M
Avg. volume:
2.7M
1-year change:
-41.15%
Market cap:
$454.4M
Revenue:
$20K
EPS (TTM):
-$1.34

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALT
Altimmune
$560 -$0.34 -88.8% -7.65% $22.38
AMGN
Amgen
$8.9B $5.34 8.14% 257.4% $315.95
LLY
Eli Lilly and
$14.2B $5.47 45.75% 89.16% $1,006.63
PFE
Pfizer
$13.5B $0.57 -3.03% 29.69% $31.32
TERN
Terns Pharmaceuticals
-- -$0.33 -- -7.38% $19.06
VKTX
Viking Therapeutics
-- -$0.36 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALT
Altimmune
$5.90 $22.38 $454.4M -- $0.00 0% 20,948.16x
AMGN
Amgen
$313.71 $315.95 $168.5B 41.55x $2.38 2.91% 5.07x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
PFE
Pfizer
$25.72 $31.32 $145.8B 18.24x $0.43 6.57% 2.30x
TERN
Terns Pharmaceuticals
$3.18 $19.06 $269.7M -- $0.00 0% --
VKTX
Viking Therapeutics
$30.89 $99.29 $3.5B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALT
Altimmune
-- 3.397 -- 12.90x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
TERN
Terns Pharmaceuticals
-- 2.694 -- --
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALT
Altimmune
-- -$24.9M -61.21% -61.21% -463580% -$18.3M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
TERN
Terns Pharmaceuticals
-- -$24.9M -- -- -- -$16.5M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Altimmune vs. Competitors

  • Which has Higher Returns ALT or AMGN?

    Amgen has a net margin of -463600% compared to Altimmune's net margin of 6.9%. Altimmune's return on equity of -61.21% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALT
    Altimmune
    -- -$0.33 $123.5M
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About ALT or AMGN?

    Altimmune has a consensus price target of $22.38, signalling upside risk potential of 279.24%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.71%. Given that Altimmune has higher upside potential than Amgen, analysts believe Altimmune is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALT
    Altimmune
    5 2 0
    AMGN
    Amgen
    9 14 2
  • Is ALT or AMGN More Risky?

    Altimmune has a beta of 0.869, which suggesting that the stock is 13.083% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock ALT or AMGN?

    Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. Altimmune pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios ALT or AMGN?

    Altimmune quarterly revenues are $5K, which are smaller than Amgen quarterly revenues of $9.1B. Altimmune's net income of -$23.2M is lower than Amgen's net income of $627M. Notably, Altimmune's price-to-earnings ratio is -- while Amgen's PE ratio is 41.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 20,948.16x versus 5.07x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
    AMGN
    Amgen
    5.07x 41.55x $9.1B $627M
  • Which has Higher Returns ALT or LLY?

    Eli Lilly and has a net margin of -463600% compared to Altimmune's net margin of 32.59%. Altimmune's return on equity of -61.21% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALT
    Altimmune
    -- -$0.33 $123.5M
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About ALT or LLY?

    Altimmune has a consensus price target of $22.38, signalling upside risk potential of 279.24%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Altimmune has higher upside potential than Eli Lilly and, analysts believe Altimmune is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALT
    Altimmune
    5 2 0
    LLY
    Eli Lilly and
    16 4 0
  • Is ALT or LLY More Risky?

    Altimmune has a beta of 0.869, which suggesting that the stock is 13.083% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock ALT or LLY?

    Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Altimmune pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ALT or LLY?

    Altimmune quarterly revenues are $5K, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Altimmune's net income of -$23.2M is lower than Eli Lilly and's net income of $4.4B. Notably, Altimmune's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 20,948.16x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns ALT or PFE?

    Pfizer has a net margin of -463600% compared to Altimmune's net margin of 2.31%. Altimmune's return on equity of -61.21% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALT
    Altimmune
    -- -$0.33 $123.5M
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About ALT or PFE?

    Altimmune has a consensus price target of $22.38, signalling upside risk potential of 279.24%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Altimmune has higher upside potential than Pfizer, analysts believe Altimmune is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALT
    Altimmune
    5 2 0
    PFE
    Pfizer
    6 13 1
  • Is ALT or PFE More Risky?

    Altimmune has a beta of 0.869, which suggesting that the stock is 13.083% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock ALT or PFE?

    Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Altimmune pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios ALT or PFE?

    Altimmune quarterly revenues are $5K, which are smaller than Pfizer quarterly revenues of $17.8B. Altimmune's net income of -$23.2M is lower than Pfizer's net income of $410M. Notably, Altimmune's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 20,948.16x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
    PFE
    Pfizer
    2.30x 18.24x $17.8B $410M
  • Which has Higher Returns ALT or TERN?

    Terns Pharmaceuticals has a net margin of -463600% compared to Altimmune's net margin of --. Altimmune's return on equity of -61.21% beat Terns Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ALT
    Altimmune
    -- -$0.33 $123.5M
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
  • What do Analysts Say About ALT or TERN?

    Altimmune has a consensus price target of $22.38, signalling upside risk potential of 279.24%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 500.39%. Given that Terns Pharmaceuticals has higher upside potential than Altimmune, analysts believe Terns Pharmaceuticals is more attractive than Altimmune.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALT
    Altimmune
    5 2 0
    TERN
    Terns Pharmaceuticals
    5 3 0
  • Is ALT or TERN More Risky?

    Altimmune has a beta of 0.869, which suggesting that the stock is 13.083% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ALT or TERN?

    Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALT or TERN?

    Altimmune quarterly revenues are $5K, which are larger than Terns Pharmaceuticals quarterly revenues of --. Altimmune's net income of -$23.2M is lower than Terns Pharmaceuticals's net income of -$21.9M. Notably, Altimmune's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 20,948.16x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
  • Which has Higher Returns ALT or VKTX?

    Viking Therapeutics has a net margin of -463600% compared to Altimmune's net margin of --. Altimmune's return on equity of -61.21% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ALT
    Altimmune
    -- -$0.33 $123.5M
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About ALT or VKTX?

    Altimmune has a consensus price target of $22.38, signalling upside risk potential of 279.24%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Altimmune has higher upside potential than Viking Therapeutics, analysts believe Altimmune is more attractive than Viking Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALT
    Altimmune
    5 2 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is ALT or VKTX More Risky?

    Altimmune has a beta of 0.869, which suggesting that the stock is 13.083% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock ALT or VKTX?

    Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALT or VKTX?

    Altimmune quarterly revenues are $5K, which are larger than Viking Therapeutics quarterly revenues of --. Altimmune's net income of -$23.2M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Altimmune's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 20,948.16x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Goldman Sachs Stock a Buy Sell or Hold?
Is Goldman Sachs Stock a Buy Sell or Hold?

When the Federal Reserve started hiking rates in 2022, banks’…

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock